Literature DB >> 8120623

Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation.

J W Polli1, R L Kincaid.   

Abstract

Cyclic nucleotide-dependent protein phosphorylation plays a central role in neuronal signal transduction. Neurotransmitter-elicited increases in cAMP/cGMP brought about by activation of adenylyl and guanylyl cyclases are downregulated by multiple phosphodiesterase (PDE) enzymes. In brain, the calmodulin (CaM)-dependent isozymes are the major degradative activities and represent a unique point of intersection between the cyclic nucleotide- and calcium (Ca2+)-mediated second messenger systems. Here we describe the distribution of the PDE1B1 (63 kDa) CaM-dependent PDE in mouse brain. An anti-peptide antiserum to this isoform immunoprecipitated approximately 30-40% of cytosolic PDE activity, whereas antiserum to PDE1A2 (61 kDa isoform) removed 60-70%, demonstrating that these isoforms are the major CaM-dependent PDEs in brain. Quantification of PDE1B1 immunoreactivity on immunoblots indicated that striatum contains 3-17-fold higher levels of PDE1B1 than other brain regions, with lowest immunoreactivity in cerebellum. In situ hybridization demonstrated high levels of PDE1B1 mRNA in the caudate-putamen, nucleus accumbens, and olfactory tubercle. Moderate mRNA levels were observed in dentate gyrus, cerebral cortex, medial thalamic nuclei, and brainstem, whereas negligible mRNA was detectable in the globus pallidus, islands of Calleja, substantia nigra, and ventral tegmental area. Immunocytochemistry confirmed that the majority of PDE1B1 protein was localized to the caudate-putamen, nucleus accumbens, and olfactory tubercle. Within the caudate-putamen, PDE1B1 immunoreactivity was ubiquitous, while PDE1A2 immunostaining was restricted to a minor subset of striatal neurons. The expression of PDE1B1 protein and mRNA correlate strongly with areas of the brain that are richest in dopaminergic innervation; indeed, there are strikingly similar distributions for PDE1B1 and D1 dopamine receptor mRNAs. Since D1 receptor binding activates adenylyl cyclase, and striatal neurons lack CaM-sensitive forms of cyclase, the high amount of this PDE implies an important physiological role for Ca(2+)-regulated attenuation of cAMP-dependent signaling pathways following dopaminergic stimulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120623      PMCID: PMC6577553     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  32 in total

1.  Quantitative assessment of transcriptome differences between brain territories.

Authors:  Michel de Chaldée; Marie-Claude Gaillard; Nicolas Bizat; Jean-Marie Buhler; Olivier Manzoni; Joël Bockaert; Philippe Hantraye; Emmanuel Brouillet; Jean-Marc Elalouf
Journal:  Genome Res       Date:  2003-07       Impact factor: 9.043

2.  Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation.

Authors:  M Sitges; V Nekrassov
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

3.  Molecular components of striatal plasticity: the various routes of cyclic AMP pathways.

Authors:  A Rajadhyaksha; J Leveque; W Macías; A Barczak; C Konradi
Journal:  Dev Neurosci       Date:  1998       Impact factor: 2.984

4.  Immunohistochemical localization of calmodulin-dependent cyclic phosphodiesterase in the human brain.

Authors:  S Lal; R K Sharma; C McGregor; R J Macaulay
Journal:  Neurochem Res       Date:  1999-01       Impact factor: 3.996

5.  Striatal neurones have a specific ability to respond to phasic dopamine release.

Authors:  Liliana R V Castro; Marina Brito; Elvire Guiot; Marina Polito; Christoph W Korn; Denis Hervé; Jean-Antoine Girault; Danièle Paupardin-Tritsch; Pierre Vincent
Journal:  J Physiol       Date:  2013-04-03       Impact factor: 5.182

Review 6.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

7.  Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases.

Authors:  R R Reinhardt; E Chin; J Zhou; M Taira; T Murata; V C Manganiello; C A Bondy
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  KS-505a, an isoform-selective inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase.

Authors:  M Ichimura; R Eiki; K Osawa; S Nakanishi; H Kase
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

Review 9.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

10.  Prediction and validation of a mechanism to control the threshold for inhibitory synaptic plasticity.

Authors:  Yuichi Kitagawa; Tomoo Hirano; Shin-ya Kawaguchi
Journal:  Mol Syst Biol       Date:  2009-06-16       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.